Physician profile
Theodore Feldman
NPI 1457390965
$636,805.71
in general payments reported to CMS, 2019-2025
25 companies · $27K in 2025
The $27K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117K · 2020: $125K · 2021: $141K · 2022: $106K · 2023: $54K · 2024: $67K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $130K · Travel and Lodging: $15K · Food and Beverage: $3,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $130,300.06 |
| Travel and Lodging | $14,950.91 |
| Food and Beverage | $3,037.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $424,615.92 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $118,812.60 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52,856.12 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $26,245.74 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $8,487.50 | 2019-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $3,743.51 | 2021-2023 | Arcalyst |
| Medtronic Vascular, INC. | $514.38 | 2019-2020 | |
| Medtronic, INC. | $338.44 | 2022-2025 | Symplicity G3 |
| Impulse Dynamics (USA) INC. | $195.41 | 2023 | Optimizer, Optimizer |
| Atricure, INC. | $166.01 | 2023 | |
| Pfizer INC. | $144.07 | 2019-2025 | |
| Amgen INC. | $114.43 | 2019-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $104.40 | 2019-2024 | Camzyos |
| Sanofi-Aventis U.S. LLC | $84.03 | 2019 | |
| Akcea Therapeutics, INC. | $68.09 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $56.96 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $46.58 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $39.84 | 2024 | Arcalyst |
| Gilead Sciences, INC. | $36.25 | 2019 | |
| Boston Scientific Corporation | $35.94 | 2019 | |
| Abiomed | $26.90 | 2024 | Impella |
| Abbott Laboratories | $23.39 | 2021 | |
| Aegerion Pharmaceuticals, INC. | $19.26 | 2019 | |
| Amarin Pharma, INC. | $15.52 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.